Gene Editing Market: Exploring Future Business Opportunities
This press release from Coherent Market Insights details a research report on the Gene Editing Market, forecasting substantial growth from 2026 to 2033. The report analyzes key market trends, drivers, challenges, and competitive landscapes, featuring major players like CRISPR Therapeutics and Editas Medicine. It provides insights into market segmentation, geographical landscapes, and future opportunities to aid businesses in strategic decision-making.
Editas Medicine’s Volatile Comeback: Can CRISPR Hype Outrun Clinical Risk?
Editas Medicine's stock has shown extreme volatility, driven by new CRISPR data and a divided Wall Street. Despite a 40-60% gain for investors over the past year, the stock remains well below its historical peaks, leading to profit-taking and cautious analyst ratings. The company's future hinges on continuous clinical progress, effective balance sheet management, and favorable regulatory and competitive developments in the gene-editing sector.
Editas Medicine’s Volatile Comeback: Can CRISPR Hype Outrun Clinical Risk?
Editas Medicine's stock has experienced significant volatility due to a split market opinion on its CRISPR-based gene editing technology. Despite a respectable one-year return for investors who bought at the lows, the stock remains well below its historical peaks, reflecting ongoing clinical risks and competitive pressures. Wall Street analysts maintain a cautiously skeptical stance, viewing it as a speculative investment tied to future clinical data and financial management.
Editas Medicine (NASDAQ:EDIT) Share Price Crosses Below Fifty Day Moving Average - Time to Sell?
Editas Medicine (NASDAQ:EDIT) saw its share price fall below its fifty-day moving average, reaching a low of $1.67. The stock currently has a "Moderate Buy" consensus rating from analysts with an average target price of $5.00, despite a recent upgrade from Chardan Capital to "strong-buy" and a reiterated "sell" from Weiss Ratings. The company exceeded revenue and EPS estimates in its last quarterly report but remains unprofitable with a negative net margin and return on equity, though institutional investors hold a significant stake.
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR
The Gene Editing Market is projected to grow from US$ 4.80 Bn in 2025 to US$ 9.51 Bn by 2032, expanding at a CAGR of 10.2%. This detailed report by Coherent Market Insights analyzes market dynamics, competitive landscapes, and future opportunities, segmenting the market by product type, application, end-user, and region. Key players include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, with the study aimed at providing strategic insights for businesses and stakeholders.
Editas Medicine (NASDAQ:EDIT) Share Price Crosses Below 50 Day Moving Average - Here's What Happened
Editas Medicine (NASDAQ:EDIT) saw its share price fall below its 50-day moving average on Wednesday, reaching $1.95 after trading as low as $1.93. Analyst sentiment for the gene-editing company is mixed, with a "Moderate Buy" consensus and a $5.00 target price, despite the company reporting better-than-expected Q4 earnings but remaining unprofitable. Institutional investors have recently adjusted their holdings in Editas Medicine, with a significant portion of the stock owned by these firms.
🚨EPSTEIN FILES: JEFFREY EPSTEIN HAD MORGAN STANLEY RESEARCH ON CRISPR GENE EDITING COMPANY A February 2016 Morgan Stanley report on Editas Medicine was found in Epstein's files. The report is titled "Starting A Gene Editing Revolu
A Morgan Stanley research report from February 2016 on Editas Medicine, titled "Starting A Gene Editing Revolu," was discovered in Jeffrey Epstein's files. The article suggests a potential connection between Epstein and research into CRISPR gene editing. However, the exact content of the report regarding this connection is not detailed.
Editas Medicine achieves significant LDL reduction with EDIT-401 therapy
Editas Medicine has announced a significant breakthrough in LDL cholesterol reduction with its experimental gene-editing therapy, EDIT-401, which achieved a mean reduction of 90% or more in non-human primates. This therapy is positioned as a potential best-in-class, one-time treatment for managing cholesterol levels. The development represents a major advancement in the field of in vivo gene editing, holding promise for future therapies.
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Brokerages
Editas Medicine, Inc. (NASDAQ:EDIT) has received an average "Moderate Buy" rating from six brokerage firms, with an average 12-month price target of $5.00. Institutional investors have significantly increased their holdings in the company. The gene-editing biotechnology firm reported stronger-than-expected earnings and revenue for its last quarter.
Individual investors who hold 55% of Editas Medicine, Inc. (NASDAQ:EDIT) gained 14%, institutions profited as well
Individual investors collectively own 55% of Editas Medicine, Inc. (NASDAQ:EDIT), making them the largest shareholder group and influencing key decisions. Both individual investors and institutions, which hold a 45% stake, benefited from a recent US$28 million market cap gain. The company's shares are widely disseminated, with the top 25 shareholders controlling less than half, and insiders hold a small minority stake.
Individual investors who hold 55% of Editas Medicine, Inc. (NASDAQ:EDIT) gained 14%, institutions profited as well
Individual investors collectively own 55% of Editas Medicine, Inc. (NASDAQ:EDIT), indicating significant influence over company decisions and benefiting most from a recent 14% gain in the stock. Institutional investors also profited from this rise, holding a respectable stake, but top shareholders collectively control less than half of the company's shares. Insiders, however, hold less than 1% of the company's stock and have recently sold shares.
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 |
The global gene editing tools market is projected to reach US$ 1,700.05 million by 2033, growing at a CAGR of 15.0% from its 2024 valuation of US$ 450.12 million. This growth is driven by rapid technological advancements in gene-editing platforms like CRISPR/Cas9, the rise of personalized medicine, and expanding applications across various diseases. North America currently leads the market with a 40% share, supported by strong biotechnology infrastructure and research funding.
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Editas Medicine, Inc. (NASDAQ:EDIT) has received a "Moderate Buy" consensus recommendation from six brokerages, with an average 12-month target price of $5.00. While the company exceeded Q4 earnings and revenue estimates, it remains unprofitable, facing a forecast of -2.71 EPS for the current fiscal year. Despite these financial challenges, institutional ownership remains high at 71.90%, with significant stake increases from major firms indicating continued investor interest in the gene-editing biotechnology company.
Editas Medicine (NASDAQ:EDIT) Shares Cross Below 50-Day Moving Average - Time to Sell?
Editas Medicine (NASDAQ:EDIT) shares recently dropped below their 50-day moving average, signaling short-term technical weakness, despite quarterly results that surpassed analyst expectations but showed deep unprofitability. Analysts have a mixed "Hold" consensus rating with an average target price of $4.29, although individual ratings vary from "Strong Buy" to "Sell". Institutional ownership remains high at 71.90%, with some increasing their stakes in the company.
Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
Analysts have upgraded revenue forecasts for Editas Medicine, Inc. (NASDAQ:EDIT) after its latest quarterly results, with revenues beating estimates by 53%. Despite an expected 66% decline in revenue for 2026 and ongoing losses, analysts reconfirmed their loss per share estimates and maintained a consensus price target of US$4.00, indicating the business is performing largely as expected. The company's revenue decline is projected to accelerate, performing worse than the wider industry.
Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop
Editas Medicine, Inc. (NASDAQ:EDIT) has seen a 29% share price drop in the last month, contributing to an 11% decline over the past year. This underperformance is reflected in its low price-to-sales (P/S) ratio of 6.4x compared to the Biotech industry average. The company's revenue decreased by 42% in the last year, with analysts expecting a further 36% annual decline over the next three years, justifying the current low P/S and raising concerns about future price stability.
Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates
Editas Medicine (NASDAQ:EDIT) recently reported its quarterly earnings, exceeding revenue estimates by 53% despite recording a statutory loss. Analysts have responded by boosting their revenue estimates for 2026, though the consensus price target remains unchanged at US$4.00 due to concerns about ongoing losses and a projected revenue decline compared to the wider industry.
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
Editas Medicine reported its financial results for the third quarter of 2025, highlighting significant progress with its lead in vivo candidate, EDIT-401, designed to reduce LDL cholesterol. The company presented preclinical data showing over 90% LDL-C reduction in non-human primates and extended its cash runway into Q3 2027. Editas Medicine plans to file an IND/CTA for EDIT-401 by mid-2026 and expects initial human proof-of-concept data by year-end 2026.
Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?
Editas Medicine, a CRISPR licensee, is making a third attempt at gene editing therapy after failures in treating eye disease and sickle cell disease/beta thalassemia. The company is now targeting high LDL ("bad") cholesterol, a mass-market indication, distinguishing itself from peers focusing on smaller populations. Despite previous setbacks and a beaten-down stock, the author suggests that EDIT's focus on a large target market and pioneering in-the-body editing capability offers a favorable reward-risk balance.
Editas Medicine at H. C. Wainwright: Aiming for LDL-C Breakthrough By Investing.com - Investing.com Canada
This article from Investing.com Canada aims to cover Editas Medicine's presentation at H.C. Wainwright, focusing on their efforts to achieve a breakthrough in treating LDL-C. However, due to an application error, the full content of the article is unavailable.
Prime Capital Investment Advisors LLC Lowers Stock Position in Editas Medicine, Inc. $EDIT - Defense World
Prime Capital Investment Advisors LLC decreased its holdings in Editas Medicine, Inc. (EDIT) during the second quarter. Despite this, other institutions increased their stakes in the company. Editas Medicine's stock recently fell by 8.8%, and analysts have set a price objective of $5.00 with a "buy" rating.
Editas Medicine Reports Promising Preclinical Data for LDL-Cholesterol-Lowering Gene Editing Therapy EDIT-401 at ESGCT Congress
Editas Medicine presented promising preclinical data for its gene editing therapy, EDIT-401, at the ESGCT Congress, showing over 90% reduction in LDL cholesterol in non-human primates and mice. The therapy utilizes a CRISPR/Cas9 approach to enhance LDL receptor expression for durable cholesterol reduction. Insider trading data for EDIT shows more sales than purchases, while institutional investors have mixed activity.
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Editas Medicine announced in vivo preclinical proof-of-concept data for EDIT-401, an experimental gene-editing therapy aimed at significantly reducing LDL-cholesterol. The data, presented at the ESGCT 32nd Annual Congress, showed a mean LDL-C reduction of ≥90% in non-human primates and mouse models within 48 hours of a single dose. This indicates EDIT-401's potential as a transformative, one-time therapy for high LDL cholesterol by upregulating the LDL receptor.
Editas Medicine reports 90% LDL-C reduction in preclinical studies
Editas Medicine (NASDAQ:EDIT) presented preclinical data for its experimental gene therapy EDIT-401, showing a significant 90% reduction in LDL cholesterol levels within 48 hours in non-human primates and sustained effects in mouse models. The therapy utilizes CRISPR/Cas9 gene editing and is being developed as a potential one-time treatment for high LDL cholesterol. This promising data was presented at the European Society of Gene and Cell Therapy Congress, reinforcing the potential of their upregulation strategy.
Editas Medicine to Present Groundbreaking LDL-Cholesterol-Lowering CRISPR Gene Editing Research at ESGCT Congress 2025
Editas Medicine announced it will present groundbreaking CRISPR gene editing research for lowering LDL cholesterol at the ESGCT Congress on October 9, 2025. The presentation will highlight findings from mouse and non-human primate studies showing functional upregulation of LDLR. Editas Medicine also plans to participate in several investor conferences in October, underscoring its commitment to engaging with the scientific and investment communities.
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
Editas Medicine announced an oral presentation of its EDIT-401 program at the European Society of Gene and Cell Therapy (ESGCT) Congress. The presentation will detail how EDIT-401 functions as a transformative LDL-cholesterol-lowering in vivo CRISPR gene editing medicine. Additionally, Editas Medicine management will participate in two upcoming investor conferences in October: the H.C. Wainwright Genetic Medicines Virtual Conference and the Chardan 9th Annual Genetic Medicines Conference.
While institutions invested in Editas Medicine, Inc. (NASDAQ:EDIT) benefited from last week's 11% gain, individual investors stood to gain the most
Individual investors collectively hold 53% of Editas Medicine, Inc. (NASDAQ:EDIT), giving them significant influence and the greatest potential benefit from stock fluctuations, following a recent 11% gain. Institutions own 47%, with top holders including The Vanguard Group, Inc. and BlackRock, Inc., while insiders hold less than 1% of the shares.
Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Editas Medicine, Inc.'s shares have risen 26% in the last thirty days, yet the stock is still down 21% over the past year. Despite its low price-to-sales (P/S) ratio of 6.4x compared to the industry average, the company's revenue has declined by 42% in the last year and is forecast to decrease 36% per annum over the next three years, while the broader industry is expected to grow by 120% annually. This suggests that the low P/S ratio reflects concerns about its lack of growth.
Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Editas Medicine, Inc. (NASDAQ:EDIT) shares jumped 26% in the last thirty days, but the stock is still down 21% over the last twelve months. Despite its current price-to-sales ratio, the company's revenue has declined by 42% over the last year and is forecast to decrease by another 36% annually over the next three years, while the broader biotech industry is expected to grow by 120% annually. This weak outlook for shrinking revenue contributes to its low P/S ratio, and analysts believe the potential for improvement is not great enough to justify a higher valuation.
After strategic pivot, Editas lays out plan to target high cholesterol with gene editing
Editas Medicine has nominated EDIT-401 as its lead in vivo gene editing candidate, a one-time therapy targeting high cholesterol by editing the LDLR gene. This strategic pivot follows a dramatic reduction in head count and a shift away from rare genetic diseases. If successful, the company aims to submit IND filings by mid-2026 and believes its current cash reserves will fund operations into Q2 2027.
Editas Medicine Announces Nomination of EDIT-401 as Lead Development Candidate with Promising Preclinical Results in LDL-C Reduction | EDIT Stock News
Editas Medicine has nominated EDIT-401 as its lead development candidate, an in vivo gene therapy designed to significantly reduce LDL cholesterol (LDL-C). Preclinical studies in non-human primates showed an approximately 90% reduction in LDL-C, significantly outperforming current therapies. The company aims for human proof-of-concept data by the end of 2026 and expects its strong cash position to fund operations into the second quarter of 2027.
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
Editas Medicine, a gene editing company, will host a webinar on September 2, 2025, to announce the selection of its lead in vivo development candidate. The company focuses on using CRISPR genome editing systems to develop transformative in vivo medicines for serious diseases. The webinar will be accessible via webcast and a replay will be available on their investor relations website.
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine announced its participation in three investor conferences in September 2025: the Wells Fargo Healthcare Conference, the Cantor Global Healthcare Conference, and the Baird Global Healthcare Conference. Management will engage in one-on-one meetings, and for the Cantor conference, there will be a webcasted fireside chat. The company, a gene editing pioneer, aims to develop transformative in vivo medicines using CRISPR technology.
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
Editas Medicine reported its Q2 2025 financial results, highlighting progress towards nominating its first in vivo development candidate in September and filing an IND by mid-2026. The company also announced the first IND/CTA acceptance for its CD19 HD Allo CAR T program, triggering a milestone payment from Bristol Myers Squibb. Editas maintains a strong cash position, expecting its operational runway to extend into the second quarter of 2027.
Editas Medicine narrows losses as Bristol Myers Squibb partnership hits key milestone
Editas Medicine reported Q2 2025 financial results, showing a narrowed net loss of $53.2 million and a strong cash position providing a runway into Q2 2027. The company reached a key milestone with the acceptance of the first IND/CTA for its CD19 HD Allo CAR T program in collaboration with Bristol Myers Squibb, triggering a milestone payment and validating its gene editing technology for potential autoimmune disease treatments. Editas also plans to select its first in vivo development candidate in September, aiming for an IND filing by mid-2026 and human proof-of-concept by year-end 2026.
Editas Medicine - Primed For An Unlikely Comeback? It's Not Impossible
Editas Medicine's stock has faced significant challenges due to clinical setbacks, but a renewed focus on in-vivo gene editing, particularly in addressing HSCs and liver, offers a glimmer of hope. Despite patent disputes and competition, the company is valued near its cash levels of $221 million, and its proprietary LNP delivery system could be a differentiator. While it remains a high-risk investment, a clinical breakthrough might lead to a quick doubling of the stock, offering speculative upside for risk-tolerant investors.
Numerous Editas Medicine Insiders Sold Stock: Not A Positive Omen
Over the last year, multiple insiders at Editas Medicine (NASDAQ:EDIT) have sold shares, with no insider purchases reported. While the total value of insider selling in the last three months was modest at US$28k, the absence of buying combined with low overall insider ownership (US$953k) raises some concerns for shareholders. The article suggests that while insider selling alone isn't always a red flag, a pattern of sales and low ownership warrants a deeper look.
Top 10 CRISPR Stocks to Buy Now
The gene-editing market, particularly CRISPR-Cas9 technology, is experiencing rapid growth, with the U.S. market projected to reach $13.99 billion by 2034. This article identifies top CRISPR stocks based on performance and hedge fund interest, highlighting companies like Editas Medicine, Inc. with significant advancements in genetic disease treatments. The analysis utilizes hedge fund holdings to recommend leading investment opportunities in this innovative biopharmaceutical sector.
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
Editas Medicine is a clinical-stage biotech company focused on CRISPR gene-editing technology for rare conditions. While their in vivo gene editing approach shows promise with encouraging animal test results and potential for widespread applications, the company faces significant challenges. These include unproven human efficacy, strong competition, weak financials with recurring losses, and the need for future funding, making it a highly speculative investment.
News: CMN Weekly (13 June 2025) - Your Weekly CRISPR Medicine News
This "CMN Weekly" newsletter provides a roundup of the latest developments in CRISPR medicine, covering top picks like Vertex's CASGEVY extended follow-up data, new research on RNA acetylation and off-target prediction, and industry partnerships. It also highlights advancements in clinical trials for various diseases and discusses recent reviews and perspectives on CRISPR technology, including its media portrayal.
RFK Jr. Just Supercharged These 2 Biotech Penny Stocks
Following an announcement by Health and Human Services Secretary Robert F. Kennedy Jr. regarding accelerated drug approvals for rare diseases, biotech penny stocks Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT) have gained significant attention. Both companies specialize in gene-editing platforms and are expected to benefit from the new regulatory framework. While offering potentially high upside, these speculative investments also carry considerable risks and volatility.
Editas Medicine Reports Promising In Vivo Gene Editing Results for Sickle Cell Disease and Beta Thalassemia at ASGCT Annual Meeting
Editas Medicine reported promising in vivo gene editing results for sickle cell disease and beta thalassemia, demonstrating therapeutically relevant editing levels in hematopoietic stem cells using a proprietary targeted lipid nanoparticle. The studies in humanized mice and non-human primates exceeded the 25% editing threshold required for therapeutic benefit, with efficient de-targeting of the liver. These findings support Editas' approach to developing a transformative gene-edited medicine using its AsCas12a technology.
ToolGen and Vertex focus battle over CRISPR/Cas therapy Casgevy in Europe
ToolGen has filed a patent infringement lawsuit against Vertex's CRISPR/Cas therapy Casgevy in the UK, seeking an injunction and a worldwide licensing agreement for its proprietary CRISPR RNP technology. This move follows ToolGen's prior announcement of legal action and Vertex's pre-emptive nullity suit against ToolGen's patent in the Netherlands. The litigation marks an escalation in the long-standing dispute over CRISPR/Cas patents, which previously played out primarily in patent offices and has now reached civil courts in Europe.
GC Therapeutics Appoints Kai-Hsin Chang as Head of Drug Development, SVP and Azadeh Golipour as Head of Technical Operations, SVP
GC Therapeutics, a biotechnology company focused on iPSC-based cell therapies, has appointed two new executives. Kai-Hsin Chang, Ph.D., formerly of Editas Medicine, joins as Head of Drug Development, SVP, bringing expertise in regulatory strategy and translational medicine. Azadeh Golipour, Ph.D., previously with AVROBIO, will serve as Head of Technical Operations, SVP, and is expected to leverage her experience in manufacturing and scaling gene and cell therapies.
Arbor Raises $73.5M To Ride Out Gene Editing’s ‘Gartner Hype Cycle’
Arbor Biotechnologies has successfully closed a $73.5 million Series C funding round, bringing its total capital and partnerships to over $1 billion. This funding will advance its CRISPR-based genetic therapies targeting liver and central nervous system conditions, including a lead candidate for primary hyperoxaluria type 1 (PH1). Despite recent setbacks in the gene editing sector, Arbor remains optimistic, leveraging its differentiated Cas12 platform and a significant partnership with Vertex Pharmaceuticals to navigate the "Gartner hype cycle" of gene editing.
Editas Medicine Progresses Towards Two In Vivo Editing Development Candidates by Mid-2025 and Expands Research Pipeline
Editas Medicine is advancing its in vivo gene editing pipeline, aiming to declare two development candidates in hematopoietic stem cells and liver by mid-2025, with further preclinical data expected by year-end. Despite a significant net loss in 2024 and restructuring following the discontinuation of the reni-cel program, the company maintains a strong cash position into Q2 2027. This progress underscores the potential of its gene upregulation platform to address serious diseases.
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?
This article discusses why Editas Medicine, Inc. (EDIT) is considered a top CRISPR stock, highlighting the significant growth and innovation within the gene therapy and gene editing market. It details the company's focus on in vivo CRISPR gene-editing programs and its lead candidate, EDIT-301, for sickle cell disease and beta-thalassemia, leveraging promising preclinical results and strategic pivots to extend its cash runway. The piece also touches on regulatory advancements and investment trends in the biotech sector.
Cambridge biotech company lays off more than half its employees
Editas Medicine Inc., a Cambridge-based biotech company, is laying off 180 employees, or 65% of its workforce. The company is discontinuing its lead reni-cel program, an experimental treatment for sickle cell disease and transfusion-dependent beta thalassemia, after failing to secure a partnership or out-license the project. Editas was the first gene editing company to go public in 2016.
Editas lays off 65% of staff, including CMO, after fruitless search for reni-cel partner
Editas Medicine is laying off 65% of its workforce, including its chief medical officer, after failing to find a partner for its sickle cell disease (SCD) medicine, reni-cel. The company will cease development of reni-cel and pivot its focus to in vivo gene therapy programs, aiming to extend its cash reserves until Q2 2027. This strategic shift comes despite positive clinical data for reni-cel but against the backdrop of an approved competitor therapy for SCD.
Gene-editing pioneer Editas lays off more than half its employees
Editas Medicine, a gene-editing pioneer, is laying off 180 workers, more than half its employees, as it shifts its focus strictly to in-vivo gene editing. The Cambridge biotech is also dropping its lead program. This move comes eight years after the company became the first gene editing company to go public.
